Pivotal clinical trials for trastuzumab biosimilars

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Pivotal clinical trials for trastuzumab biosimilars

INICIO/Informes | Posted 06/11/2015 0 Post your comment

Biosimilars of Roche’s Herceptin (trastuzumab), a humanized monoclonal antibody are currently under development.

Trastuzumab interferes with the human epidermal growth factor receptor 2 (HER2)/neu receptor. In some cancers, notably certain types of breast cancer, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably. Trastuzumab is therefore used to treat certain breast cancers.

Pivotal trials for candidate trastuzumab biosimilars being carried out typically include just one study of the response rate with some progression-free survival (PFS) data. The trials take 24–48 months and are tougher trials to recruit and execute than anti-tumour necrosis factor (TNF) trials [1], see Table 1.

Table 1: Pivotal clinical trials for candidate trastuzuzumab biosimilars

Editor’s Comment
If you would like to receive a high resolution copy of Figure 1* please send us an email.

_{*For profit organizations subjected to a fee.}

Related articles

Pivotal clinical trials for rituximab biosimilars

Pivotal clinical trials for bevacizumab biosimilars

Clinical programs for oncology biosimilars

References
1. Gal R. Biosimilars: at the inflection point. 13th EGA-European Biosimilars Group Conference; 23–24 April 2015; London, UK.
2. GaBI Online - Generics and Biosimilars Initiative. US$67 billion worth of biosimilar patents expiring before 2020 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Nov 6]. Available from: www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.